Lennart Tonneijck1, Marcel H A Muskiet1, Mark M Smits1, Petter Bjornstad2, Mark H H Kramer1, Michaela Diamant1, Ewout J Hoorn3, Jaap A Joles4, Daniël H van Raalte1. 1. Department of Internal Medicine, Diabetes Center, VU University Medical Center, Amsterdam, The Netherlands. 2. Department of Pediatric Endocrinology, University of Colorado School of Medicine and Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, Colorado. 3. Department of Internal Medicine, Division of Nephrology and Transplantation, Erasmus Medical Center, Rotterdam, The Netherlands. 4. Department of Nephrology and Hypertension, University Medical Center, Utrecht, The Netherlands.
Abstract
AIMS: To determine the effects of glucagon-like peptide (GLP)-1 receptor agonists (RA) on uric acid (UA) levels and kidney UA clearance. MATERIAL AND METHODS: This study involved post-hoc analyses of 4 controlled clinical trials, which assessed actions of GLP-1RA administration on kidney physiology. The immediate effects of GLP-1RA exenatide infusion vs placebo were determined in 9 healthy overweight men (Study-A) and in 52 overweight T2DM patients (Study-B). The effects of 12 weeks of long-acting GLP-1RA liraglutide vs placebo in 36 overweight T2DM patients (Study-C) and of 8 weeks ofshort-acting GLP-1RA lixisenatide vs once-daily titrated insulin glulisine in 35 overweight T2DM patients (Study-D) were also examined. Plasma UA, fractional (inulin-corrected) and absolute urinary excretion of UA (UEUA ) and sodium (UENa ), and urine pH were determined. RESULTS:Median baseline plasma UA level was 5.39 to 6.33 mg/dL across all studies (17%-22% of subjects were hyperuricaemic). In Study-A, exenatide infusion slightly increased plasma UA (+0.07 ± 0.02 mg/dL, P = .04), and raised absolute-UEUA (+1.58 ± 0.65 mg/min/1.73 m2 , P = .02), but did not affect fractional UEUA compared to placebo. Fractional UEUA and absolute UEUA correlated with increases in urine pH (r:0.86, P = .003 and r:0.92, P < .001, respectively). Fractional UEUA correlated with increased fractional UENa (r:0.76, P = .02). In Study-B, exenatide infusion did not affect plasma UA, but increased fractional UEUA (+0.76 ± 0.38%, P = .049) and absolute UEUA (+0.75 ± 0.27 mg/min/1.73 m2 , P = .007), compared to placebo. In regression analyses, both parameters were explained by changes in urine pH and, in part, by changes in UENa . In Study-C, liraglutide treatment did not affect plasma UA, UEUA, UENa or urine pH, compared to placebo. In Study-D, lixisenatide treatment increased UENa and urine pH from baseline, but did not affect plasma UA or UEUA . CONCLUSION:Immediate exenatide infusion increases UEUA in overweight healthy men and in T2DM patients, probably by inhibiting Na+ /H+ -exchanger type-3 in the renal proximal tubule. Prolonged treatment with a long-acting or short-acting GLP-1RA does not affect plasma UA or UEUA in T2DM patients with normal plasma UA levels and at relatively low cardiovascular risk. Our results suggest that the cardio-renal benefits of GLP-1RA are not mediated through changes in UA.
RCT Entities:
AIMS: To determine the effects of glucagon-like peptide (GLP)-1 receptor agonists (RA) on uric acid (UA) levels and kidney UA clearance. MATERIAL AND METHODS: This study involved post-hoc analyses of 4 controlled clinical trials, which assessed actions of GLP-1RA administration on kidney physiology. The immediate effects of GLP-1RA exenatide infusion vs placebo were determined in 9 healthy overweight men (Study-A) and in 52 overweight T2DM patients (Study-B). The effects of 12 weeks of long-acting GLP-1RA liraglutide vs placebo in 36 overweight T2DM patients (Study-C) and of 8 weeks of short-acting GLP-1RA lixisenatide vs once-daily titrated insulinglulisine in 35 overweight T2DM patients (Study-D) were also examined. Plasma UA, fractional (inulin-corrected) and absolute urinary excretion of UA (UEUA ) and sodium (UENa ), and urine pH were determined. RESULTS: Median baseline plasma UA level was 5.39 to 6.33 mg/dL across all studies (17%-22% of subjects were hyperuricaemic). In Study-A, exenatide infusion slightly increased plasma UA (+0.07 ± 0.02 mg/dL, P = .04), and raised absolute-UEUA (+1.58 ± 0.65 mg/min/1.73 m2 , P = .02), but did not affect fractional UEUA compared to placebo. Fractional UEUA and absolute UEUA correlated with increases in urine pH (r:0.86, P = .003 and r:0.92, P < .001, respectively). Fractional UEUA correlated with increased fractional UENa (r:0.76, P = .02). In Study-B, exenatide infusion did not affect plasma UA, but increased fractional UEUA (+0.76 ± 0.38%, P = .049) and absolute UEUA (+0.75 ± 0.27 mg/min/1.73 m2 , P = .007), compared to placebo. In regression analyses, both parameters were explained by changes in urine pH and, in part, by changes in UENa . In Study-C, liraglutide treatment did not affect plasma UA, UEUA, UENa or urine pH, compared to placebo. In Study-D, lixisenatide treatment increased UENa and urine pH from baseline, but did not affect plasma UA or UEUA . CONCLUSION: Immediate exenatide infusion increases UEUA in overweight healthy men and in T2DM patients, probably by inhibiting Na+ /H+ -exchanger type-3 in the renal proximal tubule. Prolonged treatment with a long-acting or short-acting GLP-1RA does not affect plasma UA or UEUA in T2DM patients with normal plasma UA levels and at relatively low cardiovascular risk. Our results suggest that the cardio-renal benefits of GLP-1RA are not mediated through changes in UA.
Authors: Rury R Holman; M Angelyn Bethel; Robert J Mentz; Vivian P Thompson; Yuliya Lokhnygina; John B Buse; Juliana C Chan; Jasmine Choi; Stephanie M Gustavson; Nayyar Iqbal; Aldo P Maggioni; Steven P Marso; Peter Öhman; Neha J Pagidipati; Neil Poulter; Ambady Ramachandran; Bernard Zinman; Adrian F Hernandez Journal: N Engl J Med Date: 2017-09-14 Impact factor: 91.245
Authors: Michelle P Kao; Donald S Ang; Stephen J Gandy; M Adnan Nadir; J Graeme Houston; Chim C Lang; Allan D Struthers Journal: J Am Soc Nephrol Date: 2011-06-30 Impact factor: 10.121
Authors: Jennifer S Ten Kulve; Dick J Veltman; Liselotte van Bloemendaal; Frederik Barkhof; Madeleine L Drent; Michaela Diamant; Richard G IJzerman Journal: Diabetes Care Date: 2015-08-17 Impact factor: 19.112
Authors: Johannes F E Mann; David D Ørsted; Kirstine Brown-Frandsen; Steven P Marso; Neil R Poulter; Søren Rasmussen; Karen Tornøe; Bernard Zinman; John B Buse Journal: N Engl J Med Date: 2017-08-31 Impact factor: 91.245
Authors: Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse Journal: N Engl J Med Date: 2016-06-13 Impact factor: 176.079
Authors: Sabrina M Nielsen; Else M Bartels; Marius Henriksen; Eva E Wæhrens; Henrik Gudbergsen; Henning Bliddal; Arne Astrup; Filip K Knop; Loreto Carmona; William J Taylor; Jasvinder A Singh; Fernando Perez-Ruiz; Lars E Kristensen; Robin Christensen Journal: Ann Rheum Dis Date: 2017-09-02 Impact factor: 19.103
Authors: Danii Ls Suijk; Mark M Smits; Marcel Ha Muskiet; Lennart Tonneijck; Mark Hh Kramer; Jaap A Joles; Daniël H van Raalte Journal: Nephrology (Carlton) Date: 2019-09-12 Impact factor: 2.506
Authors: Emma J Bouman; Mark M Smits; Erik J van Bommel; Marcel H A Muskiet; Anne C Hesp; Erik H Serné; Jaap A Joles; Daniël H van Raalte Journal: Microcirculation Date: 2021-05-06 Impact factor: 2.628